Here, we used a previously generated aromatase-overexpressing T47D cell that was letrozole-sensitive (T47Darom) or letrozole-resistant (T47DaromLR) to test the hypothesis that targeting ER and HER2 will trigger anti-proliferative effects selective to letrozole-resistant breast cancer cells. Here, ESR1 is linked to breast carcinoma.